Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
28 août 2018 07h00 HE
|
Oxford BioMedica plc
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and...